Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SHMT2 | P34897 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6279616 | 0.94 | SOAT1 (0.54) | SOAT1TP53LMNAPOLBSHMT2 | |
| Trifluoroacetic Acid SCHEMBL6280105 | 0.85 | SOAT1 (0.53) | SOAT1LMNAPOLBDRD2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL1705470 | 0.79 | SOAT1 (0.52) | SOAT1LMNAPOLBNPC1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6282019 | 0.73 | SOAT1 (0.41) | SOAT1LMNADRD2DRD3KDM4E | |
| Trifluoroacetic Acid SCHEMBL1704553 | 0.72 | TMEM97 (0.48) | SOAT1LMNAKDM4ENPC1ALDH1A1 | |
| SCHEMBL6278513 | 0.71 | SOAT1 (0.90) | SOAT1 | |
| Trifluoroacetic Acid SCHEMBL5623338 | 0.70 | ALDH1A1 (0.40) | SOAT1LMNAKDM4ENPC1ALDH1A1 | |
| SCHEMBL6282732 | 0.69 | SOAT1 (0.86) | SOAT1 | |
| SCHEMBL6283820 | 0.69 | SOAT1 (0.91) | SOAT1POLB | |
| SCHEMBL8157356 | 0.68 | SOAT1 (0.91) | SOAT1TP53LMNAPOLBSHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969711-B2 | Cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| EP-0987254-B1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | KOWA CO (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-0987254-A1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2000-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | LCAT, ACAT2, ACAT1 | SOAT1 5/4885TP53 4601/4885LMNA 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.